Thursday, March 14, 2013
Publication and contact
progression by measuring the evolution of mutational heterogeneity in cancer
Computational analysis of
patient whole-exome sequencing data could be used to measure the evolution of
tumor heterogeneity and help predict disease progression. Whole-exome
sequencing and subsequent computational analysis of 149 samples from patients
with chronic lymphocytic leukemia (CLL) identified more than 3,000 mutations
in total and quantified the prevalence of mutations in each cancer sample. In
12 matched patient samples taken before and after chemotherapy, sequence
analysis identified driver mutations that expanded in prevalence after
treatment and predicted poor survival. Next steps include determining whether
the presence of these driver mutations or the measurement of
chemotherapy-induced tumor evolution can predict patient outcomes in
prospective clinical trials.
Published online March 14, 2013
Patent applications filed;
available for licensing and freely available for academic and not-for-profit
Landau, D.A. et al. Cell;
published online Feb. 14, 2013;
Contact: Catherine J. Wu,
Dana-Farber Cancer Institute, Boston, Mass.
Contact: Gad Getz, Broad Institute of MIT and Harvard, Cambridge,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]